(Q36235502)

12 August 2017

1 reference

title

The safety and tolerability of atypical antipsychotics in bipolar disorder (English)

1 reference

12 August 2017

1 reference

Florian Seemüller

1

0 references

Heinz Grunze

object named as

Heinz Grunze

7

0 references

author name string

Anna Forsthoff

2

1 reference

12 August 2017

Sandra Dittmann

3

1 reference

12 August 2017

Christoph Born

4

1 reference

12 August 2017

Britta Bernhard

5

1 reference

12 August 2017

W Emanuel Severus

6

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 September 2005

1 reference

Expert Opinion on Drug Safety

12 August 2017

published in

1 reference

12 August 2017

volume

4

1 reference

12 August 2017

issue

5

1 reference

12 August 2017

page(s)

849-868

1 reference

Selection of atypical antipsychotics for the management of schizophrenia

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.5.849

Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.5.849

Acute and continuation risperidone monotherapy in bipolar mania: a 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.5.849

Aripiprazole: in acute mania associated with bipolar I disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.5.849

Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.5.849

Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.5.849

Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.5.849

A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.5.849

The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders, Part II: Treatment of Mania

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.5.849

The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders, part III: maintenance treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.5.849

Olanzapine: a review of its use in the management of bipolar I disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.5.849

Olanzapine versus divalproex in the treatment of acute mania

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.5.849

Quetiapine versus placebo in combination with lithium or divalproex for the treatment of bipolar mania

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.5.849

Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.5.849

Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.5.849

Height, weight and body mass index (BMI) in psychiatrically ill US Armed Forces personnel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.5.849

Obesity as a correlate of outcome in patients with bipolar I disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.5.849

The associations between psychopathology and being overweight: a 20-year prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.5.849

Updating the evidence that physical activity is good for health: an epidemiological review 2000-2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.5.849

Effects of exercise training on older patients with major depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.5.849

Impact of waist circumference on the relationship between blood pressure and insulin: the Quebec Health Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.5.849

Waist circumference, visceral obesity, and cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.5.849

Metabolic dysregulation with atypical antipsychotics occurs in the absence of underlying disease: a placebo-controlled study of olanzapine and risperidone in dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.5.849

Evaluation of insulin sensitivity in healthy volunteers treated with olanzapine, risperidone, or placebo: a prospective, randomized study using the two-step hyperinsulinemic, euglycemic clamp

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.5.849

Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or placebo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.5.849

Side effects of atypical antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.5.849

Risperidone-associated transient diabetic ketoacidosis and diabetes mellitus type 1 in a patient treated with valproate and lithium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.5.849

Burden of general medical conditions among individuals with bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.5.849

Mood-altering effects of biperiden in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.5.849

Kaplan Award 1998. Epidemiology of chronic daily headache in the general population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.5.849

Prevalence, Clinical Correlates, and Treatment of Migraine in Bipolar Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.5.849

Management of bipolar disorder during pregnancy and the postpartum period

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.5.849

Lamotrigine and the risk of malformations in pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.5.849

Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.5.849

Cross-national epidemiology of major depression and bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.5.849

Prevalence of obesity and weight change during treatment in patients with bipolar I disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.5.849

21 January 2018

Identifiers

DOI

10.1517/14740338.4.5.849

1 reference

12 August 2017

1 reference